The Global Melanoma Drugs Market Will Reach $89bn In 2018

LONDON - April 20, 2018 - PRLog -- A new report by visiongain calculates that the global melanoma drugs market will reach $89bn in 2018 with revenues showing growth to 2028. These revenue forecasts and others appear in visiongain's latest report Global Melanoma Drugs Market 2018-2028: By Kinase Inhibitors, By Immunotherapeutic Agents, By Chemotherapeutic Agents, Tafinlar, Mekinist, Zelbroaf, Yervoy, Proleukin, Keytruda, PegIntron, Roferon-A, Dacarbazine, Temodar/Temodal and Leading Companies. Visiongain is a leading market intelligence company based in London, UK.

Following two decades of little or no developments, the melanoma drugs market has undergone a period of rejuvenation of the last few years. This has aided the market in growing revenue significantly. New innovative technologies geared towards diverse modes of action are now employed to tackle melanoma. With new drugs aimed at immune checkpoint inhibition and cell signalling pathways now entering this market and in the development pipeline, the market for melanoma drugs looks set for rapid growth over the next decade. There are currently a handful of drugs used in the treatment of late stage and malignant melanoma. These drugs have been classed into three categories. These include: chemotherapeutic drugs such as Dacarbazine and Temodar, kinase inhibitors such as Dabrafenib (Tafinlar) and Trametinib (Mekinist), and immunotherapeutic drugs such as Ipilimumab (Yervoy) and Pembrolizumab (Keytruda).

A senior pharmaceutical and medical technology market analyst at Visiongain explains: "The market for malignant melanoma drugs is undergoing a period of rapid innovation, whereby novel technologies are being developed. The development pipeline appears strong, and these products and an array of combination therapies being trialled should become available for the treatment of melanoma over the next decade. The rising incidence of malignant melanoma coupled with the shift towards treatment personalisation will also contribute to market expansion. However, high development costs and inadequate reimbursement structures may act to hinder the growth of the melanoma drugs market."

Improved patient compliance coupled with the rising melanoma incidence amidst a growing global population offer added incentive for growth. Targeted therapies in oncology have progressively become more selective for particular mutations, allowing drugs to be specifically designed to provide clinical benefit to a subset of identifiable patients. Improvements in disease free survival for late-stage malignant melanoma such as the PD-1 inhibitors and immunotherapeutics will stimulate market growth.

Visiongain's brand new report provides revenue forecasts to 2028 for the global melanoma drugs market and its leading regional markets. It forecasts sales for the US

Canada, Mexico, Brazil, Argentina, Paraguay, Bolivia, France, Germany, UK, Spain, Italy, Russia, China, Japan, India, Australia, Thailand, Middle East and Africa.

The report also forecasts sales for subsectors of the melanoma drugs market. These include the kinase inhibitors, immunotherapeutics, and chemotherapeutics segments of the market. Analysis and forecasts for key marketed products in each of these segments are provided together with profiles, analysis, and forecasts of products in the development pipeline.

The report also includes analysis of strengths, weaknesses, opportunities and threats to the market, as well as porter's five forces analyses examining the powers of suppliers and buyers, the threat of substitutes and new entrants, and the rivalry amongst competitors in the market.

Global Melanoma Drugs Market 2018-2028: By Kinase Inhibitors, By Immunotherapeutic Agents, By Chemotherapeutic Agents, Tafinlar, Mekinist, Zelbroaf, Yervoy, Proleukin, Keytruda, PegIntron, Roferon-A, Dacarbazine, Temodar/Temodal and Leading Companies adds to visiongain's extensive range of analytical reports on industries and markets in healthcare.

For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongain.com

Tel: +44 (0) 20 7549 9987

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987

About visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional who needs independent, high quality, original analyses to inform their strategic decisions.